These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 24470751)

  • 1. Does fesoterodine have a role in the treatment of poorly managed patients with overactive bladder?
    Morris V; Wagg A
    Drug Des Devel Ther; 2014; 8():113-9. PubMed ID: 24470751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
    Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
    BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fesoterodine clinical efficacy and safety for the treatment of overactive bladder in relation to patient profiles: a systematic review.
    Chapple C; Oelke M; Kaplan SA; Scholfield D; Arumi D; Wagg AS
    Curr Med Res Opin; 2015 Jun; 31(6):1201-43. PubMed ID: 25798911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptoms.
    Grenabo L; Herschorn S; Kaplan SA; Cardozo L; Scholfield D; Arumi D; Carlsson M; Chapman D; Ntanios F
    Curr Med Res Opin; 2017 Oct; 33(10):1731-1736. PubMed ID: 28758802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of the efficacy and safety of fesoterodine for treating overactive bladder and urgency urinary incontinence in elderly patients.
    Wagg A; Oelke M; Angulo JC; Scholfield D; Arumi D
    Drugs Aging; 2015 Feb; 32(2):103-25. PubMed ID: 25673122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
    DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
    Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A role of fesoterodine in treatment of overactive bladder].
    Kupriyanov YA; Kasyan GR; Pushkar DY
    Urologiia; 2018 Dec; (6):155-162. PubMed ID: 30742396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fesoterodine fumarate.
    Gomelsky A; Dmochowski RR
    Drugs Today (Barc); 2010 Feb; 46(2):81-90. PubMed ID: 20393636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fesoterodine: a new agent for treating overactive bladder.
    Ellsworth P; Berriman SJ; Brodsky M
    Am J Manag Care; 2009 Mar; 15(4 Suppl):S115-7. PubMed ID: 19355800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review.
    Gacci M; Novara G; De Nunzio C; Tubaro A; Schiavina R; Brunocilla E; Sebastianelli A; Salvi M; Oelke M; Gravas S; Carini M; Serni S
    BMC Urol; 2014 Oct; 14():84. PubMed ID: 25348235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
    Cardozo L; Thorpe A; Warner J; Sidhu M
    BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pooled analysis of the efficacy of fesoterodine for the treatment of overactive bladder, and the relationship between safety, co-morbidity and polypharmacy in patients aged 65 years or older.
    Wagg A; Arumi D; Herschorn S; Angulo Cuesta J; Haab F; Ntanios F; Carlsson M; Oelke M
    Age Ageing; 2017 Jul; 46(4):620-626. PubMed ID: 28057620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicriteria Decision Analysis Applied to the Clinical Use of Pharmacotherapy for Overactive Bladder Symptom Complex.
    Chapple CR; Mironska E; Wagg A; Milsom I; Diaz DC; Koelbl H; Pushkar D; Tubaro A; De Ridder D; Chartier-Kastler E; Phillips LD
    Eur Urol Focus; 2020 May; 6(3):522-530. PubMed ID: 31623981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fesoterodine for the treatment of overactive bladder.
    Tzefos M; Dolder C; Olin JL
    Ann Pharmacother; 2009 Dec; 43(12):1992-2000. PubMed ID: 19920160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of fesoterodine in women with overactive bladder.
    Sand PK; Morrow JD; Bavendam T; Creanga DL; Nitti VW
    Int Urogynecol J Pelvic Floor Dysfunct; 2009 Jul; 20(7):827-35. PubMed ID: 19495545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
    Kaplan SA; Roehrborn CG; Rovner ES; Carlsson M; Bavendam T; Guan Z
    JAMA; 2006 Nov; 296(19):2319-28. PubMed ID: 17105794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of fesoterodine fumarate in patients with overactive bladder: results of a post-marketing surveillance study in Korea.
    Kim TH; Lee SE; Lee HE; Lee KS
    Curr Med Res Opin; 2016 Aug; 32(8):1361-6. PubMed ID: 27046653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: An open-label, flexible-dosing, multicentre study.
    Swift SE; Siami P; Forero-Schwanhaeuser S
    Clin Drug Investig; 2009; 29(5):305-16. PubMed ID: 19366272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.